Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.9209
Nov 20 • 3:58 PM ET Dollar change-0.0629 Percentage change(-6.39%)
Aftermarket Close
0.9209
Aftermarket • 7:30 PM ET Dollar change0.0000 Percentage change(0.00%)
Index
-
Market Cap
66.61M
Enterprise Value
22.31M
Income
-127.33M
Sales
25.17M
Book/sh
-0.24
Cash/sh
2.03
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
229
IPO
Mar 25, 2015
P/E
-
Forward P/E
-
PEG
-
P/S
2.65
P/B
-
P/C
0.45
P/FCF
-
EV/EBITDA
-
EV/Sales
0.89
Quick Ratio
1.15
Current Ratio
1.15
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
-1.27
EPS next Y
-0.86
EPS next Q
-0.26
EPS this Y
-80.77%
EPS next Y
28.60%
EPS next 5Y
-28.02%
EPS past 3/5Y
33.81% 18.84%
Sales past 3/5Y
56.25% -0.34%
EPS Y/Y TTM
-279.52%
Sales Y/Y TTM
-66.55%
EPS Q/Q
-10613.79%
Sales Q/Q
-89.26%
Insider Own
3.93%
Insider Trans
0.00%
Inst Own
13.17%
Inst Trans
1.07%
ROA
-45.76%
ROE
-307.38%
ROIC
-179.69%
Gross Margin
148.51%
Oper. Margin
-518.02%
Profit Margin
-505.89%
SMA20
-16.57%
SMA50
-25.28%
SMA200
-67.73%
Trades
Shs Outstand
72.33M
Shs Float
69.48M
52W High
5.45 -83.10%
52W Low
0.88 4.55%
Volatility
11.00% 10.66%
ATR (14)
0.13
RSI (14)
37.74
Beta
3.12
Rel Volume
0.46
Avg Volume
113.65K
Volume
52,636
Perf Week
-21.96%
Perf Month
-5.55%
Perf Quarter
-71.13%
Perf Half Y
-73.69%
Perf YTD
-80.97%
Perf Year
-80.73%
Perf 3Y
-70.29%
Perf 5Y
-89.66%
Perf 10Y
-94.86%
Prev Close
0.98
Price
0.92
Change %
-6.39%
Consensus
Hold
Avg. Price Target
$4.75
Implied Upside
+415.8%
Analysts12incl. previous ratings
Rating Distribution6 Buy · 4 Hold · 2 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 16, 2026Downgrade
BCS logoBBarclays
Overweight → Underweight$1.30+41.2%
Sep 15, 2026Downgrade
CCitizens
Mkt Outperform → Mkt Perform
May 28, 2026Initiated
BCS logoBBarclays
Overweight$9+877.3%
Feb 17, 2026Resumed
JEF logoJJefferies
Buy$7+660.1%
Mar 17, 2023Initiated
BBryan Garnier
Buy$6+551.5%
May 18, 2022Upgrade
RRobert W. Baird
Neutral → Outperform$10+985.9%
Jan 06, 2022Downgrade
WFC logoWWells Fargo
Overweight → Equal Weight$39 → $16+1,637.4%
Nov 30, 2021Initiated
JJMP Securities
Mkt Outperform$20+2,071.8%
Nov 08, 2021Downgrade
WWilliam Blair
Outperform → Mkt Perform
Oct 08, 2021Downgrade
RRobert W. Baird
Outperform → Neutral$39 → $10+985.9%
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and Andre Choulika on February 20, 1999 and is headquartered in Paris, France.
Co-FounderDr. Andre Choulika Ph.D.
Co-FounderDr. David J. Sourdive Ph.D.
CFO & Chief Business OfficerMr. Arthur Stril
Principal Financial Officer & Principal Accounting OfficerValerie Cros
Chief Technological OfficerMr. Jean Charles Epinat Ph.D.